Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure
for producing such polypeptides by recombinant techniques is disclosed. Also disclosed
are methods for utilize such ICE LAP-6 for the treatment of a susceptibility to
viral infection, tumorogenesis and to diseases and defects in the control embryogenesis
and tissue homeostasis, and the nucleic acid sequences described above may be employed
in an assay for ascertaining such susceptibility. Antagonists against such ICE
LAP-6 and their use as a therapeutic to treat Alzheimer's disease, Parkinson's
disease, rheumatoid arthritis, septic shock, sepsis, stroke, chronic inflammation,
acute inflammation, CNS inflammation, osteoporosis, ischemia reperfusion injury,
cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis
of endothelial cells in cardiovascular disease, degenerative liver disease, MS,
ALS, cererbellar degeneration ischemic injury, myocardial infarction, AIDS, myelodysplastic
syndromes, aplastic anemia, male pattern baldness, and head injury damage are also
disclosed. Also disclosed are diagnostic assays for detecting diseases related
to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.
Also disclosed are diagnostic assays for detecting mutations in the polynucleotides
encoding the interleukin-1 beta converting enzyme apoptosis proteases and for detecting
altered levels of the polypeptide in a host.
